论文部分内容阅读
目的探讨恶性肿瘤患者尿液中可溶性尿激酶受体(suPAR)和胱抑素C(Cystatin C)水平及与治疗的关系。方法 suPAR采用ELISA法检测。Cystatin C应用颗粒增强散射免疫比浊法(PENIA)检测,使用德灵BNII特定蛋白分析仪;对照组为82例健康成人,病例组为93例恶性肿瘤患者,比较2组尿液中suPAR和Cystatin C的检测水平。结果恶性肿瘤患者尿液中suPAR和Cystatin C水平较对照组增高,差异有统学意义(P<0.01)。结论与健康对照成人比较恶性肿瘤患者尿液中suPAR和Cystatin C水平增高,且与恶性肿瘤患者手术有关。检测恶性肿瘤患者尿液中suPAR和Cystatin C水平有可能成为新的诊断和预后判断指标,对恶性肿瘤患者病情监测和疗效判断具有较高的临床价值。
Objective To investigate the relationship between the levels of suPAR and Cystatin C in urine of patients with malignant tumor and its relationship with treatment. Methods suPAR was detected by ELISA. Cystatin C was detected by particle-enhanced immunosorbent assay (PENIA) using Delin BNII specific protein analyzer. The control group was 82 healthy adults and 93 patients with malignant tumor. The levels of suPAR and Cystatin C detection level. Results The levels of suPAR and Cystatin C in urine of patients with malignant tumors were significantly higher than those of the control group (P <0.01). Conclusions The levels of suPAR and Cystatin C in urine of patients with malignant tumors are higher than those of healthy controls, and are related to the operation of patients with malignant tumors. Detection of suPAR and Cystatin C in urine of patients with malignant tumors may become a new diagnostic and prognostic indicator, and has a high clinical value for monitoring the disease and judging the therapeutic effect in patients with malignant tumors.